Wurz GT - Search Results

1

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

Soe LH, Wurz GT, Kao CJ, Degregorio MW. Soe LH, et al. Among authors: wurz gt. Int J Womens Health. 2013 Sep 25;5:605-11. doi: 10.2147/IJWH.S39146. Int J Womens Health. 2013. PMID: 24109197 Free PMC article. Review.

2

A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

DeGregorio M, Wurz G, Emshoff V, Koester S, Minor P, Wiebe V. DeGregorio M, et al. Breast Cancer Res Treat. 1992;24(1):35-41. doi: 10.1007/BF01832356. Breast Cancer Res Treat. 1992. PMID: 1463870

3

Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Baker WJ, Wiebe VJ, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, DeGregorio MW. Baker WJ, et al. Among authors: wurz gt. Breast Cancer Res Treat. 1992;24(1):43-9. doi: 10.1007/BF01832357. Breast Cancer Res Treat. 1992. PMID: 1463871

4

Flow cytometry: potential utility in monitoring drug effects in breast cancer.

Koester SK, Maenpaa JU, Wiebe VJ, Baker WJ, Wurz GT, Seymour RC, Koehler RE, DeGregorio MW. Koester SK, et al. Among authors: wurz gt. Breast Cancer Res Treat. 1994;32(1):57-65. doi: 10.1007/BF00666206. Breast Cancer Res Treat. 1994. PMID: 7819587 Review.

5

A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin.

Maenpaa JU, Wurz GT, Baker WJ, Wiebe VJ, Emshoff VD, Koester SK, Seymour RC, Koehler RE, DeGregorio MW. Maenpaa JU, et al. Among authors: wurz gt. Oncol Res. 1993;5(12):461-6. Oncol Res. 1993. PMID: 8086667

6

Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.

Baker WJ, Maenpaa JU, Wurz GT, Koester SK, Seymour RC, Emshoff VD, Wiebe VJ, DeGregorio MW. Baker WJ, et al. Among authors: wurz gt. Oncol Res. 1993;5(6-7):207-12. Oncol Res. 1993. PMID: 8123940

7

Targeting chemosensitizing doses of toremifene based on protein binding.

Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ. Wurz GT, et al. Cancer Chemother Pharmacol. 1993;31(5):412-4. doi: 10.1007/BF00686157. Cancer Chemother Pharmacol. 1993. PMID: 8431976

8

Tissue distribution of transdermal toremifene.

Soe L, Wurz GT, Mäenpää JU, Hubbard GB, Cadman TB, Wiebe VJ, Theon AP, DeGregorio MW. Soe L, et al. Among authors: wurz gt. Cancer Chemother Pharmacol. 1997;39(6):513-20. doi: 10.1007/s002800050607. Cancer Chemother Pharmacol. 1997. PMID: 9118463

9

Haloenol lactone: a new synergist of chemotherapy in vitro.

Zheng J, Wurz GT, Cadman TB, Degregorio MW, Jones AD, Hammock BD. Zheng J, et al. Among authors: wurz gt. Biochem Biophys Res Commun. 1997 Dec 8;241(1):13-7. doi: 10.1006/bbrc.1997.7762. Biochem Biophys Res Commun. 1997. PMID: 9405226

10

Intratumoral toremifene therapy and tissue distribution in the baboon.

Wurz GT, Mäenpää JU, Hubbard GB, Cadman TB, Seymour RC, Soe L, DeGregorio MW. Wurz GT, et al. Anticancer Drugs. 1998 Feb;9(2):181-9. doi: 10.1097/00001813-199802000-00010. Anticancer Drugs. 1998. PMID: 9510505

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page